Experimental and Molecular Medicine (Nov 2023)

Circular RNA cFAM210A, degradable by HBx, inhibits HCC tumorigenesis by suppressing YBX1 transactivation

  • Jian Yu,
  • Wen Li,
  • Guo-jun Hou,
  • Da-peng Sun,
  • Yuan Yang,
  • Sheng-xian Yuan,
  • Zhi-hui Dai,
  • Hao-zan Yin,
  • Shu-han Sun,
  • Gang Huang,
  • Wei-ping Zhou,
  • Fu Yang

DOI
https://doi.org/10.1038/s12276-023-01108-8
Journal volume & issue
Vol. 55, no. 11
pp. 2390 – 2401

Abstract

Read online

Abstract Hepatitis B protein x (HBx) has been reported to promote tumorigenesis in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), but the mechanism awaits further investigation. In this study, we found that cFAM210A (a circular RNA derived from the third exon of transcript NM_001098801 of the FAM210A gene; CircBase ID: hsa_circ_0003979) can be silenced by HBx. cFAM210A expression was downregulated and negatively correlated with tumorigenesis in patients with HBV-related HCC. Furthermore, cFAM210A reduced the proliferation, stemness, and tumorigenicity of HCC cells. Mechanistically, HBx increased the N6-methyladenosine (m6A) level of cFAM210A by promoting the expression of RBM15 (an m6A methyltransferase), thus inducing the degradation of cFAM210A via the YTHDF2-HRSP12-RNase P/MRP pathway. cFAM210A bound to YBX1 and inhibited its phosphorylation, suppressing its transactivation function toward MET. These findings suggest the important role of circular RNAs in HBx-induced hepatocarcinogenesis and identify cFAM210A a potential target in the prevention and treatment of HBV-related HCC.